Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer

Slaney, C. Y., Rautela, J., & Parker, B. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1642 · Cited by 54

Doxorubicin‐induced cardiotoxicity involves IFNγ‐mediated metabolic reprogramming in cardiomyocytes

Chen, N., Ma, P., Wang, R., Lou, X., Liu, X., Qin, Y., Xue, R., Blasig, I. E., Erben, U., & Qin, Z. (2018) · The Journal of Pathology · doi:10.1002/path.5192 · Cited by 53

Natural Killer Cells: From Basic Research to Treatments

Vivier, É., & Ugolini, S. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00018 · Cited by 53

The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages

Movahedi, K., & Ginderachter, J. A. V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6704 · Cited by 53

PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy

Lee, S. Y., Jung, D. K., Choi, J. E., Jin, C., Hong, M. J., Do, S. K., Kang, H., Lee, W. K., Seok, Y., Lee, E. B., et al. (2016) · Scientific Reports · doi:10.1038/srep25952 · Cited by 54

Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy

Audsley, K. M., McDonnell, A. M., & Waithman, J. C. (2020) · Cells · doi:10.3390/cells9030565 · Cited by 54

Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials

Wang, M., Liang, H., Wang, W., Zhao, S., Cai, X., Zhao, Y., Li, C., Cheng, B., Xiong, S., Li, J., et al. (2020) · Cancer · doi:10.1002/cncr.33270 · Cited by 53

Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients

Tay, N., Laakso, E., Schweitzer, D. R., Endersby, R., Vetter, I., & Starobova, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1015746 · Cited by 64

Leveraging Long-Distance Singlet-Oxygen Transfer for Bienzyme-Locked Afterglow Imaging of Intratumoral Granule Enzymes

Wei, X., Xu, C., Cheng, P., Hu, Y., Liu, J., Xu, M., Huang, J., Zhang, Y., & Pu, K. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05012 · Cited by 52

Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies

Mousavi‐kiasary, S. M. S., Senabreh, A., Zandi, A., Pena, R., Cruz, F., Adibi, A., & Hooshmand, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060682 · Cited by 56

Improving the efficacy of cancer immunotherapy

Copier, J. P., Dalgleish, A. G., Britten, C. M., Finke, L., Gaudernack, G., Gnjatic, S., Kallen, K., Kiessling, R. W., Schuessler‐Lenz, M., Singh, H., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.017 · Cited by 52

Dendritic Cell-Based Vaccines: Clinical Applications in Breast Cancer

Gelao, L., Criscitiello, C., Espósito, A., Laurentiis, M. D., Fumagalli, L. A. M., Locatelli, M., Minchella, I., Santangelo, M. L., Placido, S. D., Goldhirsch, A., et al. (2014) · Immunotherapy · doi:10.2217/imt.13.169 · Cited by 52

Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas

Sugimoto, M., Mitsunaga, S., YOSHIKAWA, K., Kato, Y., Gotohda, N., Takahashi, S., Konishi, M., Ikeda, M., Kojima, M., Ochiai, A., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.010 · Cited by 52

Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC

Verma, C., Eremin, J. M., Robins, A., Bennett, A. J., Cowley, G., El‐Sheemy, M., Jibril, J. A., & Eremin, O. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-16 · Cited by 54

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

Finocchiaro, G., & Pellegatta, S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1754-9 · Cited by 52

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)

Singer, C. F., Pfeiler, G., Hubalek, M., Bartsch, R., Stöger, H., Pichler, A., Petru, E., Bjelic‐Radisic, V., Greil, R., Rudas, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.018 · Cited by 52

Neem Leaf Glycoprotein Activates CD8+ T Cells to Promote Therapeutic Anti-Tumor Immunity Inhibiting the Growth of Mouse Sarcoma

Mallick, A., Barik, S., Goswami, K. K., Banerjee, S., Ghosh, S., Sarkar, K., Bose, A., & Baral, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0047434 · Cited by 51

Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer.

Battaglia, A., Buzzonetti, A., Martinelli, E., Fanelli, M., Petrillo, M., Ferrandina, G., Scambia, G., & Fattorossi, A. (2010) · International Journal of Radiation Oncology, Biology, Physics · doi:10.1016/j.ijrobp.2009.10.014 · Cited by 50

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

Heinrich, B., Klein, J. C., Delic, M., Goepfert, K., Engel, V., Geberzahn, L., Lusky, M., Erbs, P., Préville, X., & Moehler, M. H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126320 · Cited by 55

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?

Qiao, M., Jiang, T., Ren, S., & Zhou, C. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.005 · Cited by 53

Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

Xu, J. J., Zhang, L., Xie, M., Li, Y., Huang, P. C., Saunders, T. L., Fox, D. A., Rosenquist, R. W., & Lin, F. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701716 · Cited by 55

Myricetin (3,3′,4′,5,5′,7-Hexahydroxyflavone) Prevents 5-Fluorouracil-Induced Cardiotoxicity

Arafah, A. M., Rehman, M. U., Ahmad, A., Alkharfy, K. M., Alqahtani, S., Jan, B. L., & Almatroudi, N. M. (2022) · ACS Omega · doi:10.1021/acsomega.1c06475 · Cited by 51

Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response

Yu, J., He, X., Wang, Z., Wang, Y., Liu, S., Li, X., & Huang, Y. (2021) · Nanoscale · doi:10.1039/d1nr03288g · Cited by 51

A Novel Oncolytic Herpes Simplex Virus Type 2 Has Potent Anti-Tumor Activity

Zhao, Q., Zhang, W., Ning, Z., Zhuang, X., Lu, H., Liang, J., Li, J., Zhang, Y., Dong, Y., Zhang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093103 · Cited by 50

Spatially Uniform Tumor Treatment and Drug Penetration by Regulating Ultrasound with Microbubbles

Ho, Y.-J., Wang, T.-C., Fan, C., & Yeh, C. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b05508 · Cited by 50

The role of immune infiltrates as prognostic biomarkers in patients with breast cancer

Baxevanis, C. N., Sofopoulos, M., Fortis, S. P., & Perez, S. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02327-7 · Cited by 49

Plant Polyphenols as Chemopreventive Agents

Nowak, R., Olech, M., & Nowacka-Jechalke, N. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00086-4 · Cited by 50

Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

Zhou, G., & Levitsky, H. I. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/124187 · Cited by 53

Cancer vaccines: Accomplishments and challenges

Pejawar‐Gaddy, S., & Finn, O. J. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.02.010 · Cited by 49

A Combined Chemoimmunotherapy Approach Using a Plasmid−Doxorubicin Complex

Bagalkot, V., Lee, I., Yu, M. K., Lee, E., Park, S., Lee, J.-H., & Jon, S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800177f · Cited by 49

New insights into metronomic chemotherapy-induced immunoregulation

Hao, Y., Yi, S., Ruan, J., Zhao, L., & Nan, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.028 · Cited by 50

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs

Martin, K., Schreiner, J., & Zippelius, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00501 · Cited by 46

An Expanding Role for Immunotherapy in Colorectal Cancer

Bever, K. M., & Le, D. T. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0037 · Cited by 49

Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony–Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells

Talleur, A. C., Triplett, B. M., Federico, S. M., Mamcarz, E. K., Janssen, W. E., Wu, J., Shook, D. R., Leung, W. H., & Furman, W. L. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.07.011 · Cited by 53

TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy

Kang, T. H., Mao, C.-P., Kim, Y. S., Kim, T. W., Yang, A. D., Lam, B. K., Tseng, S.-H., Farmer, E. A., Park, Y.-M., & Hung, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0738-2 · Cited by 51

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses

Ylösmäki, E. O., Malorzo, C., Capasso, C., Honkasalo, O., Fusciello, M., Martins, B., Ylösmäki, L., Louna, A., Feola, S., Paavilainen, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.008 · Cited by 48

cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment

Mishra, S., Charan, M., Shukla, R. K., Agarwal, P., Misri, S., Verma, A. K., Ahirwar, D. K., Siddiqui, J., Kaul, K., Sahu, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02221-0 · Cited by 50

Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma

Lim, S. H., & Levy, R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490027 · Cited by 48

Localized Low-Dose Radiotherapy for Follicular Lymphoma: History, Clinical Results, Mechanisms of Action, and Future Outlooks

Ganem, G., Cartron, G., Girinsky, T., Haas, R. L., Cosset, J. M., & Solal‐Céligny, P. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.056 · Cited by 48

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

Bellati, F., Napoletano, C., Ruscito, I., Pastore, M., Pernice, M., Antonilli, M., Nuti, M., & Panici, P. B. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9351-4 · Cited by 48

Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response

Stagg, J., Sharkey, J., Pommey, S., Young, R., Takeda, K., Yagita∥, H., Johnstone, R. W., & Smyth, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806849105 · Cited by 48

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

Leshem, Y., O'Brien, J., Liu, X., Bera, T. K., Terabe, M., Berzofsky, J. A., Bossenmaier, B., Niederfellner, G. J., Tai, C., Reiter, Y., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0330 · Cited by 48

Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response

Rawding, P. A., Bu, J., Wang, J., Kim, D., Drelich, A. J., Kim, Y. S., & Hong, S. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1752 · Cited by 50

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

Rizvi, N. A., Ademuyiwa, F. O., Cao, Z. A., Chen, H. X., Ferris, R. L., Goldberg, S. B., Hellmann, M. D., Mehra, R., Rhee, I. P., Park, J. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005920 · Cited by 52

Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation

Qin, H., Chen, Y., Wang, Z., Li, N., Sun, Q., Lin, Y., Qiu, W., Qin, Y., Chen, L., Chen, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40851-4 · Cited by 48

Advances in local and systemic drug delivery systems for post-surgical cancer treatment

Aquib, M., Juthi, A. Z., Farooq, M. A., Ali, M. G., Janabi, A. H. W., Bavi, S., Banerjee, P., Bhosale, R. B., Bavi, R., & Wang, B. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00987c · Cited by 51

Photodynamic therapy boosts anti-glioma immunity in mice: A dependence on the activities of T cells and complement C3

Li, F., Cheng, Y.-X., Lu, J.-Y., Hu, R., Wan, Q., & Feng, H. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23228 · Cited by 47

Silk Fibroin Hydrogel Reinforced With Magnetic Nanoparticles as an Intelligent Drug Delivery System for Sustained Drug Release

Haghighattalab, M., Kajbafzadeh, A. M., Baghani, M., Gharehnazifam, Z., Jobani, B. M., & Baniassadi, M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.891166 · Cited by 46

Enhanced Chemo‐Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer

Wang, M., Hu, D., Yang, Y. S., Shi, K., Li, J., Liu, Q., Li, Y., Li, R., Pan, M., Mo, D., et al. (2023) · Advanced Science · doi:10.1002/advs.202303819 · Cited by 46

Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity

Ladoire, S., Hannani, D., Vétizou, M., Locher, C., Aymeric, L., Apétoh, L., Kepp, O., Kroemer, G., Ghiringhelli, F., & Zitvogel, L. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5133 · Cited by 50

Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion

Fritzell, S., Sandén, E., Eberstål, S., Visse, E., Darabi, A., & Siesjö, P. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1449-z · Cited by 46

Synchronisation and control of proliferation in cycling cell population models with age structure

Billy, F., Clairambault, J., Fercoq, O., Gaubertt, S., Lepoutre, T., Ouillon, T., & Saito, S. (2012) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2012.03.005 · Cited by 45

Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer

Zhang, T., & Herlyn, D. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0598-y · Cited by 46

An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects

Hernández‐Gil, J., Cobaleda‐Siles, M., Zabaleta, A., Salassa, L., Calvo, J., & Rivas, J. C. M. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500080 · Cited by 46

BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice

Sorensen, J. C., Petersen, A. C., Timpani, C. A., Campelj, D. G., Cook, J., Trewin, A. J., Stojanovska, V., Stewart, M., Hayes, A., & Rybalka, E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00137 · Cited by 46

Role of Connexins 30, 36, and 43 in Brain Tumors, Neurodegenerative Diseases, and Neuroprotection

Sánchez, O. F., Rodríguez, A. V., Velasco-España, J. M., Murillo, L. C., Sutachan, J. J., & Albarracin, S.-L. (2020) · Cells · doi:10.3390/cells9040846 · Cited by 46

Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate

Ramirez, J. A. Z., Romagnoli, G. G., Falasco, B. F., Gorgulho, C. M., Fogolin, C., dos Santos, D. C., Araújo, J. P., Lotze, M. T., Ureshino, R. P., & Kaneno, R. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106495 · Cited by 46

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

Redman, J. M., Tsai, Y.-T., Weinberg, B. A., Donahue, R. N., Gandhy, S. U., Gatti-Mays, M. E., Sater, H. A., Bilušić, M., Cordes, L. M., Steinberg, S. M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab046 · Cited by 48

Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy

Xiao, W., Wang, J., Liang, M., & Song, M. (2022) · Theranostics · doi:10.7150/thno.78572 · Cited by 45

Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17

Cathomas, R. L., Rothschild, S. I., Hayoz, S., Bubendorf, L., Özdemir, B. C., Kiss, B. M., Erdmann, A. A., Aeppli, S., Mach, N., Strebel, R. T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00363 · Cited by 45

New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy

Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 47

Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy

Sun, J., Wan, Z., Chen, Y., Xu, J., Luo, Z., Parise, R. A., Diao, D., Ren, P., Beumer, J. H., Lu, B., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.039 · Cited by 45

Autophagy-targeted nanoparticles for effective cancer treatment: advances and outlook

Long, X., Yan, J., Zhang, Z., Chang, J., He, B., Sun, Y. Y., & Liang, Y. (2022) · NPG Asia Materials · doi:10.1038/s41427-022-00422-3 · Cited by 48

Metabolites as agents and targets for cancer immunotherapy

Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 57

Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy

Re, V. D., Caggiari, L., Zorzi, M. D., Talamini, R., Racanelli, V., Andrea, M. D., Buonadonna, A., Zagonel, V., Cecchin, E., Innocenti, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084940 · Cited by 43

Advances in systemic therapy for metastatic breast cancer: future perspectives

Corona, S. P., Sobhani, N., Ianza, A., Roviello, G., Mustacchi, G., Bortul, M., Zanconati, F., & Generali, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0975-5 · Cited by 44

Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?

Attili, I., Passaro, A., Pavan, A., Conte, P., de Marinis, F., & Bonanno, L. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.007 · Cited by 45

Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation

Jeevanandam, J., Tan, K. X., Danquah, M. K., Guo, H., & Turgeson, A. (2019) · Biotechnology Journal · doi:10.1002/biot.201900368 · Cited by 46

Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

Kim, J. W., Cho, Y. B., & Lee, S. (2021) · Cells · doi:10.3390/cells10030670 · Cited by 44

Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1

Zhuang, X., Zhang, W., Chen, Y., Han, X., Li, J., Zhang, Y., Zhang, Y., Zhang, S., & Liu, B. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-549 · Cited by 44

Nullifying Tumor Efflux by Prolonged Endolysosome Vesicles: Development of Low Dose Anticancer-Carbon Nanotube Drug

Lee, Y. K., Choi, J., Wang, W., Lee, S., Nam, T.-H., Choi, W. S., Kim, C.-J., Lee, J. K., Kim, S.-H., Kang, S. S., et al. (2013) · ACS Nano · doi:10.1021/nn4041206 · Cited by 44

Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets

Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I. G., Rahimi, H., Gasparri, M. L., Antonilli, M., Panici, P. B., Rughetti, A., & Nuti, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030380 · Cited by 43

Pluronic f127 encapsulated titanium dioxide nanoparticles: Evaluation of physiochemical properties for biological applications

Elamin, N. Y., Thangavelu, I., & Kumar, Е. R. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121655 · Cited by 43

Toward Rational Design of Carbon Nanodots with High Photothermal Efficiency for Tumor Photothermal Therapy †

Liu, E., Wu, J., Liang, T., Zhang, B., Tang, Z., & Qu, S. (2023) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202300101 · Cited by 43

Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING

Wang, L., Luo, R., Onyshchenko, K., Rao, X., Wang, M., Menz, B., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006235 · Cited by 45

Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer

Zhu, B., Cai, Y., Zhou, L., Zhao, L., Chen, J., Shan, X., Sun, X., You, Q., Gong, X., Zhang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55904-z · Cited by 48

High Numbers of Differentiated Effector CD4 T Cells Are Found in Patients with Cancer and Correlate with Clinical Response after Neoadjuvant Therapy of Breast Cancer

Péguillet, I., Milder, M., Louis, D., Vincent‐Salomon, A., Dorval, T., Piperno-Neumann, S., Scholl, S., & Lantz, O. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2269 · Cited by 44

Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer

Ferguson, H. J. M., Wragg, J. W., Ward, S., Heath, V. L., Ismail, T., & Bicknell, R. (2016) · Oncotarget · doi:10.18632/oncotarget.7812 · Cited by 42

Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial

Laviano, A., Calder, P. C., Schols, A. M. W. J., Lönnqvist, F., Bech, M., & Muscaritoli, M. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1634746 · Cited by 43

The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial

Li, R., Liu, Y., Yin, R., Yin, L., Li, K., Sun, C., Zhou, Z., Li, P., Tong, R., Xue, J., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.03.003 · Cited by 48

Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases

Nierop, P. M. H., Höppener, D. J., Buisman, F. E., van der Stok, E. P., Galjart, B., Balachandran, V. P., Jarnagin, W. R., Kingham, T. P., Shia, J., Mauer, M. E. L., et al. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.235 · Cited by 42

Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents

Jarosz–Biej, M., Jazowiecka-Rakus, J., Cichoń, T., Głowala‐Kosińska, M., Smolarczyk, R., Smagur, A., Malina, S., Sochanik, A., & Szala, S. (2012) · Gene Therapy · doi:10.1038/gt.2012.28 · Cited by 44

Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients

Bower, J. E., Ganz, P. A., Irwin, M. R., Cole, S. W., Carroll, J., Kuhlman, K. R., Petersen, L., Garet, D., Asher, A., Hurvitz, S. A., et al. (2022) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkac052 · Cited by 48

Platelet-derived exosomes hybrid liposomes facilitate uninterrupted singlet oxygen generation to enhance breast cancer immunotherapy

Ning, S., Zhang, X., Suo, M., Lyu, M., You, P., Jiang, Y. H., Yang, H., Lam, J. W. Y., Zhang, T., Pan, L., et al. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101505 · Cited by 42

A comprehensive review of Co3O4 nanostructures in cancer: Synthesis, characterization, reactive oxygen species mechanisms, and therapeutic applications

Bayati-Komitaki, N., Ganduh, S. H., Alzaidy, A. H., & Salavati-Niasari, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117457 · Cited by 45

Lymphoma Immunotherapy: Current Status

Zappasodi, R., de Braud, F., & Nicola, M. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00448 · Cited by 42

Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer

Ito, F., Ku, A. W., Bucsek, M. J., Muhitch, J. B., Vardam-Kaur, T., Kim, M., Fisher, D. T., Camoriano, M., Khoury, T., Skitzki, J. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143370 · Cited by 43

Natural killer cells as a promising therapeutic target for cancer immunotherapy

Kim, N., Lee, H. H., Lee, H.-J., Choi, W. S., Lee, J., & Kim, H. S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01143-y · Cited by 44

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Huo, X., Li, J., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-07791-y · Cited by 42

Mesoporous silica nanoparticle: Heralding a brighter future in cancer nanomedicine

Abbasi, M., Ghoran, S. H., Niakan, M. H., Jamali, K., Moeini, Z., Jangjou, A., Izadpanah, P., & Amani, A. M. (2021) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2021.110967 · Cited by 41

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas

Lamb, L. S., Pereboeva, L., Youngblood, S. L., Gillespie, G. Y., Nabors, B., Markert, J. M., Dasgupta, A., Langford, C. P., & Spencer, H. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-00536-8 · Cited by 43

Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis

Petrelli, F., Ferrara, R., Signorelli, D., Ghidini, A., Proto, C., Roudi, R., Sabet, M. N., Facelli, S., Garassino, M. C., Luciani, A., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0224 · Cited by 42

Dendritic cell subsets and implications for cancer immunotherapy

Chen, M. Y., Zhang, F., Goedegebuure, S. P., & Gillanders, W. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393451 · Cited by 44

The liaison between apoptotic cells and macrophages – the end programs the beginning

Weigert, A., Jennewein, C., & Brüne, B. (2009) · Biological Chemistry · doi:10.1515/bc.2009.048 · Cited by 42

Killer dendritic cells: IKDC and the others

Bonmort, M., Dalod, M., Mignot, G., Ullrich, E., Chaput, N., & Zitvogel, L. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.006 · Cited by 41

NK cells sense tumors, course of disease and treatments

Fregni, G., Perier, A., Avril, M., & Caignard, A. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18312 · Cited by 41

Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy

Du, W., Chen, C., Sun, P., Zhang, S., Zhang, J., Zhang, X., Liu, Y., Zhang, R., Yan, C., Fan, C., et al. (2020) · Nanoscale · doi:10.1039/c9nr09835f · Cited by 41

Immunotherapy for Lung Cancer

Hirschowitz, E. A., & Yannelli, J. R. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200806-048lc · Cited by 41

Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies

Cohn, I. S., Henrickson, S. E., Striepen, B., & Hunter, C. A. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200512 · Cited by 39

Drug resistance in the mouse cancer clinic

Rottenberg, S., & Borst, P. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.001 · Cited by 40

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328